DPCG has a US patent in Collaboration with KAAU

United States Patent Application 20240189264- Method for Assessing Atenolol with Precision PUBLISHED- 13/06/2024

Prof. Mirza R. Baig along with the group of researchers from King Abdul Aziz University (KAAU), Jeddah, Saudi Arabia conducted a study among hypertensive patients and analyzed the process of selecting antihypertensive medications based on biological markers.

A patent has been applied by KAAU as an intellectual property to protect the originality of the process.

The present invention relates to a method for assessing Atenolol with precision. The method for tailoring the treatment of hypertension is not just based on blood pressure but it comprises of determining the levels of C-reactive protein, blood urea, and HbA1c in hypertensive patients; stratifying patients into distinct subgroups based on the identified biomarker levels; and customizing antihypertensive treatment plans for each subgroup, wherein treatment may include, but is not limited to, beta blockers such as Atenolol.

Prof. Dr. Mirza R. Baig was included in the patent application as a consultant to help in research design and biostatistics. As a faculty collaborator, DPCG is the part of this patent.